<p>Dr. Philip Insel provides the main findings of his paper on determining clinically meaningful decline in preclinical Alzheimer disease. </p>

Dr. Philip Insel provides the main findings of his paper on determining clinically meaningful decline in preclinical Alzheimer disease.

<p>Dr. Philip Insel provides the main findings of his paper on determining clinically meaningful decline in preclinical Alzheimer disease.&nbsp;</p>

Determining clinically meaningful decline in preclinical Alzheimer disease

The Neurology Minute podcast delivers a brief daily summary of what you need to know in the field of neurology, the latest science focused on the brain, and timely topics explored by leading neurologists and neuroscientists. From the American Academy of Neurology and hosted by Stacey Clardy, MD, Ph.D., FAAN, with contributions by experts from the Neurology journals, Neurology Today, Continuum, and more.

Share Determining clinically meaningful decline in preclinical Alzheimer disease

Sign up to save your podcasts

Determining clinically meaningful decline in preclinical Alzheimer disease

Determining clinically meaningful decline in preclinical Alzheimer disease

More shows like Neurology Minute

JAMA Editors' Summary

Neurology® Podcast

NEJM This Week

Practical Neurology Podcast

JAMA Clinical Reviews

JAMA Neurology Author Interviews

JAMA Medical News

Neurology Today in 5

Annals On Call Podcast

Navigating Neuropsychology

The Clinical Problem Solvers

Harrison's PodClass: Internal Medicine Cases and Board Prep

Neurology Exam Prep Podcast

The Curious Clinicians

Continuum Audio